Payten has acquired a majority stake in Remaris
The private shareholders of Remaris have sold a 76% stake in the company to Payten d.o.o.
Remaris is the leading Croatian developer of automation software based on in-house IP, designed primarily for the food and beverage sector of hospitality services.
Payten, a member of the Asseco South Eastern Europe Group (ASEE), provides end-to-end payment industry solutions for financial and non-financial institutions, offering the highest level of expertise, maintenance and support throughout the entire portfolio, which includes card and card-less transactions.
Oaklins’ team in Croatia acted as the exclusive advisor to the seller in this transaction.
Vedran Omrčen
Co-founder, Remaris
Talk to the deal team
Related deals
Niscon Inc. has been acquired by SGPS ShowRig
Niscon Inc. has been successfully acquired by SGPS ShowRig, a global provider of staging, rigging and automation for live entertainment. The acquisition reinforces SGPS Showrig’s commitment to pushing the boundaries of innovation in the entertainment industry. By adding Niscon’s unique motion-control technology to its portfolio, SGPS Showrig strengthens its ability to deliver cutting-edge, precision-driven solutions.
Learn moreFairfest Media has acquired WTE Miami
Fairfest Media, organizer of OTM, the leading travel show in Asia, has acquired WTE Miami, the fastest-growing travel trade show in the USA. The acquisition marks a significant milestone in Fairfest’s global expansion, strengthening its presence in the Americas and beyond by leveraging decades of experience and leadership in Asia and India.
Learn moreBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Learn more